文献速递眼底病与葡萄膜炎

COVID-19疫情期间非感染性葡萄膜炎患者免疫调节与生物治疗调整及复发情况

Impact of COVID-19 pandemic on uveitis patients receiving immunomodulatory and biological therapies (COPE STUDY).
PubMed 文献 · Br J Ophthalmol · 2020-10-03

这项全国多中心前瞻性病例系列分析了2020年3月1日至6月25日期间176例非感染性葡萄膜炎患者(284眼),评估免疫调节和生物治疗的变化及复发率。结果显示91.5%患者接受系统性免疫调节治疗,其中18.0%治疗被调整;32.5%的眼发生葡萄膜炎复发,86.2%的复发者被认为与系统性免疫调节治疗改变相关。无患者随访期间感染COVID-19。

要点

  • 疫情期间葡萄膜炎专家可能倾向于减少系统性免疫调节治疗或选择较不积极的治疗策略。
  • 18.0%接受系统性免疫调节治疗的患者治疗被调整,32.5%的眼发生复发。
  • 86.2%的复发者被认为与系统性免疫调节治疗改变相关。

核心结论

  • COVID-19疫情期间,葡萄膜炎专家可能倾向于减少正在进行的系统性免疫调节治疗或对非感染性葡萄膜炎选择较不积极的治疗策略。
  • 这些患者可能面临葡萄膜炎复发的高风险。

研究设计与样本

  • 全国多中心前瞻性病例系列,收集2020年3月1日至25日June 2020期间非感染性葡萄膜炎患者数据。
  • 共纳入176例患者(284眼),平均年龄33±17.1岁,男性68例。

主要发现

  • 121眼(90例患者)被认为有活动性非感染性葡萄膜炎。
  • 7例(7.8%)患者尽管治疗专家认为需要但未接受静脉甲泼尼龙。
  • 35例(57.4%)活动性疾病患者接受了口服糖皮质激素快速减量。
  • 161例(91.5%)接受系统性免疫调节治疗,25例(14.2%)接受生物治疗;29/161例(18.0%)免疫调节治疗被调整。

关键数值与推荐

  • 主要结局指标包括糖皮质激素、免疫调节和生物治疗的变化、替代治疗的使用及葡萄膜炎复发率。
  • 无患者在随访期间感染COVID-19。

临床怎么用

  • 临床医生在疫情等特殊时期调整系统性免疫调节治疗时需权衡复发风险。
  • 对活动性非感染性葡萄膜炎患者应谨慎减量或调整免疫调节治疗,并密切监测复发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the change in the ongoing immunomodulatory (IMT) and biological therapies among patients with non-infectious uveitis (NIU), and determine the number of uveitis relapses during the COVID-19 pandemic. METHODS: In this national multicentric prospective case series, data of subjects with NIU receiving corticosteroids, systemic IMT and/or biological agents were analysed. The data collection was performed from 1 March 2020 to 25 June 2020. Main outcome measures included change in the ongoing treatments with corticosteroids, IMT and biological agents, use of alternate therapies and rates of uveitis relapse. RESULTS: In this study, 176 patients (284 eyes) with NIU (mean age: 33±17.1 years; males: 68) were included. A total of 121 eyes (90 patients) were deemed to have active NIU. Of these, seven subjects (7.8%) did not receive intravenous methylprednisolone despite need felt by the treating uveitis experts. In addition, 35 subjects (57.4%) received a rapid tapering dosage of oral corticosteroids despite active disease. A total of 161 (91.5%) subjects were receiving systemic IMT and 25 (14.2%) were on biological therapies. Overall, IMT was altered in 29/161 (18.0%) subjects. Twenty-two eyes were treated with intravitreal therapies in the study period. Fifty-three eyes (32.5%, 29 subjects) developed relapse of NIU, of which 25 subjects (86.2%) were deemed to have reactivation related to altered systemic IMT. No patient developed COVID-19 during follow-up. CONCLUSIONS: During the ongoing COVID-19 pandemic, uveitis specialists may tend to reduce the ongoing systemic IMT, or prefer less aggressive treatment strategies for NIU. These subjects may be at high risk of relapse of uveitis.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Agarwal AK, Sudharshan S, Mahendradas P, et al. Impact of COVID-19 pandemic on uveitis patients receiving immunomodulatory and biological therapies (COPE STUDY). Br J Ophthalmol. 2020. PMID: 33011688. doi:10.1136/bjophthalmol-2020-317417

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。